ELI LILLY & CO (LLY)

US5324571083 - Common Stock

867.3  +1.48 (+0.17%)

After market: 867.3 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ELI LILLY & CO

NYSE:LLY (6/12/2024, 4:22:57 PM)

After market: 867.3 0 (0%)

867.3

+1.48 (+0.17%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month51.62%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap824.29B
Shares
PE119.13
Fwd PE44.57
Dividend Yield0.62%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LLY Daily chart

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 39,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. The firm's subsidiary is POINT Biopharma Global Inc., which is a radiopharmaceutical company with a pipeline of clinical and preclinical stage radioligand therapies in development for the treatment of cancer. The firm's products are sold in over 110 countries.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr

Indianapolis INDIANA 46285

P: 13172762000

CEO: David A. Ricks

Employees: 39000

Website: https://www.lilly.com/

LLY News

News Image3 hours ago - InvestorPlace4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024

Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively.

News Image6 hours ago - BloombergMichigan’s Largest Insurer to Drop Weight-Loss Drug Coverage

Weight-loss drugs from Novo Nordisk A/S and Eli Lilly & Co. will lose coverage under many plans run by Michigan’s largest health insurer as companies grapple with whether the drugs are worth the cost.

News Image8 hours ago - InvestorPlace3 Stocks Quietly Preparing for a 10X Surge: June Edition

There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia.

News Image10 hours ago - The Motley FoolA Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge

The integration of AI and healthcare is well underway.

News Image11 hours ago - InvestorPlace7 Trending Stocks With Momentum on Their Side

Trending stocks offer an opportunity to ride momentum higher and create quick returns for daring investors.

News Image11 hours ago - InvestorPlace3 Must-Buy Stocks Before the Third Quarter

Pounce on these three must buy-stocks before the third quarter starts, and take home solid gains as they soar on an improved economy.

LLY Twits

Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example